Teclistimab targets CD3 (expressed on the T-cell surface) and BCMA (expressed on the myeloma cell surface) and is now given for those with refractory or relapsed MM with prior exposure to triple therapy (IMiD, PI, and anti-CD38). The gene discussed is CD38; the disease is Miyoshi myopathy.